Local cerebral glucose utilization (LCGU) was determined in 49 brain regions of 3-, 12-, 24-, and 33-month-old awake rats, at 30 to 120 min after administration of the dopaminergic antagonist haloperidol (HAL) at 1 mg/kg (i.p. Aging is associated with altered neurotransmission in the brains of humans and animals (Roth and Hess, 1982; Severson et al., 1982). Markers for the dopaminergic system decrease progressively with age in the brain of several animal species (Pradhan, 1980). In rats, there are age-correlated reductions of brain tyrosine hydroxylase activity, of the rate of dopamine (DA) synthesis, and of brain concentrations of DA and of its metabolites (Reis et al., 1977; Ponzio et al., 1982; Algeri et al., 1983). The number of DA receptors is reduced in older rats, with a loss of about 40% in animals aged 24 months and older, compared to 3-to 5-month-old rats (Misra et al., 1980; Joseph et al., 1981; Govoni et al., 1983).
Local cerebral glucose utilization (LCGU) was determined in 49 brain regions of 3-, 12-, 24-, and 33-month-old awake rats, at 30 to 120 min after administration of the dopaminergic antagonist haloperidol (HAL) at 1 mg/kg (i.p. 12-and 24-month rats, and in 10% of the 49 regions in 33-month-old rats. The peak effects of HAL on LCGU occurred later in the 33-month-than in the 3-monthold rats (90 and 60 min after HAL, respectively).
The behavioral effect (catalepsy) of HAL was less in old than in young rats. Age-related differences in the cerebral metabolic and behavioral responsivities of rats to HAL are not due to differences in brain concentrations of HAL, as higher concentrations are obtained in older animals (Kapetanovic, I. M., D. J. Sweeney, and S. I. Rapoport (1982) J. Pharmacol.
Exp. Ther. 227: 434-438).
The differences correlate with known agedependent structural and biochemical deficits of the central dopaminergic system and indicate reduced functioning of that system in the rat brain after 12 months of age.
Aging is associated with altered neurotransmission in the brains of humans and animals (Roth and Hess, 1982; Severson et al., 1982) . Markers for the dopaminergic system decrease progressively with age in the brain of several animal species (Pradhan, 1980) . In rats, there are age-correlated reductions of brain tyrosine hydroxylase activity, of the rate of dopamine (DA) synthesis, and of brain concentrations of DA and of its metabolites (Reis et al., 1977; Ponzio et al., 1982; Algeri et al., 1983) . The number of DA receptors is reduced in older rats, with a loss of about 40% in animals aged 24 months and older, compared to 3-to 5-month-old rats (Misra et al., 1980; Joseph et al., 1981; Govoni et al., 1983) .
Human and animal studies report age-related differences in response to centrally acting drugs (Dawson-Butterworth, 1970; Castelden and George, 1979; Altamura et al., 1983 ). An increased cataleptic effect of haloperidol (HAL) (Campbell and Baldessarini, 1981) and greater stereotypic behavior after DA agonists (Smith et al., 1978) were described in old rats. However, less stereotypic spiffing followed intrastriatal amphetamine or DA injection in old than in young rats (Joseph and Roth, 1983) . Furthermore, aged rodents responded less to conditions that require functional adaptations of the DA system. After electroconvulsive shock or exposure to cold, DA turnover increased less in old than in young rats (McNamara et al., 1977; Algeri et al., 1982) . Neither behavioral supersensitivity nor increased DA receptor number was observed in old mice after chronic HAL administration (Randall et al., 1981) .
In this study, we wanted to determine whether a reduced capacity to respond to a DA antagonist accompanies the reported structural and biochemical changes in the central DA system during aging in rats. We measured local cerebral glucose utilization (LCGU), a parameter of neuronal functional activity, using the ['4C]deoxy-Dglucose (['?]DG) method of Sokoloff et al. (1977) . We administered the DA receptor antagonist HAL (1 mg/kg) to awake Fischer-344 rats aged 3, 12, 24, or 33 months. Fischer-344 rats reach maturity by 3 months of age and their median survival is 22 to 29 months; less than 1% live to 33 months (Chesky and Rockstein, 1976; Coleman et al., 1977) . In the rat, brain DA receptor number reaches adult levels during the first 2 months of life (Bruinink et al., 1983; Karakiulakis et al., 1983) . We also quantified the cataleptic effect of HAL in 3-and 33.month-old rats.
Effects of HAL on LCGU in young mature rats have been investigated previously (McCulloch et al., 1982; Pizzolato et al., 1984) . HAL reduced LCGU in a dose-and time-dependent manner in brain regions that comprise DA pathways, and also in many other areas that do not possess DA receptors. These responses to HAL result from its antagonism of DA receptors (Creese et al., 1976) and also can influence non-DA regions by connecting pathways. Kapetanovic et al. (1982) examined the peripheral pharmacokinetics and time-dependent brain concentrations of HAL after its acute administration intraperitoneally to awake Fischer-344 rats aged 3 to 34 months. Plasma clearance of HAL was reduced in old animals, resulting in higher plasma and brain concentrations of HAL in 32. to 34.month versus 3-to 4-month rats for a given dose per kilogram of weight.
In the present study we found lesser effects of HAL in old than in young rats on two measures of brain functional activity: brain glucose utilization and behavior. The declines are not due to changes in the pharmacokinetics of HAL with age, however, because brain concentrations of HAL are higher in the old rats (Kapetanovic et al., 1982) . They reflect, therefore, reduced function of the central DA system during aging. 
Materials and Methods

Behavioral observations
Catalepsy was evaluated in 3-and 33.month-old animals at 15min intervals after HAL or vehicle Injection. and was scored on a four-point scale from 0 (no effect, animal normal) to 4 (animal completely cataleptic), as previously described (Pizzolato et al., 1984) . Measures of catalepsy were: presence and intensity of reduced spontaneous movements of the head and forelimbs; hypertonic-aklnetic posture with kyphotic trunk, extended head, broad-based support, up-turned tail; resistance and bracing to imposed horizontal displacement of the forequarters; and ptosis. All catalepsy determinations were made by a single rater (G. P. were measured with a microdensitometer (model 700-10-90, Gamma Scientific, San Diego, CA) with a 100 pm diameter aperture. Six separate determinations were made at each region in both left and right sides of the brain, and the means for the two sides were averaged. Anatomical regions were identified by comparing autoradiograms with atlases of the rat brain (Konig and Klippel, 1967; Paxinos and Watson, 1982) and, where necessary, with cresyl violet-stained sections taken adjacent to those used for autoradiography.
LCGU was calculated from brain and plasma radioactivities and from plasma glucose concentrations, using equations and constants given by Sokoloff et al. (1977 (Sokoloff, 1982) .
Behavior
The time courses of catalepsy after HAL (1 mg/kg, i.p.) in 3-and 33-month rats are shown in Figure  1 . The peak behavioral effect was significantly smaller in the aged animals (mean score, 2.78 f 0.17 (SEM)) than in the young ones (mean score, 3.50 + 0.21). In the old rats the maximal behavioral effect also was delayed. Catalepsy was first observed in 3-month rats at 15 min after HAL administration and reached the peak level at 45 min. In the 33. month-old animals, catalepsy was minimal during the first hour and
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figure 7. HAL-induced catalepsy. Catalepsy was determined in 3-month (0) and 33.mo (0) rats at 15.min intervals after administration of HAL (1 mg/ kg, i.p.). Scoring was on a scale of 0 (no effect) to 4 (completely cataleptic). Vertical bars indicate SEM; * indicates a significant difference between the mean scores for the two age groups at each time point (p < 0.05).
peaked at 105 min after HAL. Catalepsy was not seen in vehicletreated animals.
Local cerebral glucose utilization LCGU was determined in 49 brain regions at 30, 60, and 90 min after intraperitoneal injection of HAL (1 mg/kg) in 3-month rats, at 60 and 90 min after HAL in 12. and 24.month-old rats, and at 30, 60, 90, and 120 min after HAL in 33.month-old rats. The time of vehicle injection had no significant effect on LCGU in control rats of any age; therefore, these animals were combined into four groups: 3, 12, 24, and 33 months control.
LCGU in gray and white matter regions was lower by about 20% in control 33-month compared to control 3-month animals (Table I) . Average LCGU (fSEM) for all of the regions examined was 83.8 + 1.6 for 3-month-, 83.7 + 1.3 for 12.month-, 83.3 f 2.4 for 24-month-, and 65.9 f 2.6 for 33-month-old rats. Age-related declines in LCGU, measured with the ["C]DG method, have been reported in untreated male rats (Smith et al., 1980; London et al., 1981) . Most of these declines reflect a reduction in the lumped constant for ['"Cl DG during aging in the rat (Rapoport, 1983) and, thus, are artifactual.
Time course of effect of HAL on LCGU. The general time course of the effect of HAL (1 mg/kg, i.p.) on LCGU for each of the four age groups is shown in Figure 2 . As we reported previously (Pizzolato et al., 1984) in 3-month-old rats, HAL (1 mg/kg, i.p.) significantly reduced LCGU in only a few regions at 30 min after administration, whereas it produced its maximal reductions at 60 min. At 60 min, LCGU was significantly reduced in 63% of the regions examined, by an average of 21.7% for all of the regions. In 3-month-old animals, LCGU returned to near pre-drug levels in most regions at 90 min after HAL (average LCGU decline for all examined regions was 4.7%). A similar pattern was observed in 12. and 24-month-old rats, in which the maximal response to HAL was at 60 min after treatment (significant declines were found in 23% and 21% of the regions examined, respectively). The time course of the cerebral metabolic effects of HAL was different in 33.month-old rats, however. In these animals no significant declines in LCGU were observed at 30 and 60 min after HAL, but a peak metabolic effect occurred at 90 min, when LCGU in 10% of the regions was reduced significantly (overall mean reduction 7.8%). At 120 min after HAL, no significant reductions were observed in any brain region of 33-month rats.
It was reported previously that LCGU returns to near-control levels shortly after the peak effect of HAL (Pizzolato et al., 1984) . Because this recovery is not due to a decrease in DA receptor blockade (Kuhar et al., 1978) it was ascribed to compensatory mechanisms such as formation of new receptors or altered rates of DA turnover (Moleman et al., 1978; Meller et al., 1980) .
Maximal age-dependent decline in LCGU. Table II shows LCGU values for 49 brain regions after HAL administration, expressed as percentage of age-matched control values, at the time of the maximal metabolic effect of HAL (1 mg/kg, i.p.). The time points are at 60 mm after HAL for 3-, 12., and 24.mo-old rats, and at 90 min after HAL for 33.month-old animals. LCGU values for control and HAL (1 mg/kg)-treated 3-month-old rats have been reported previously (Pizzolato et al., 1984) . Metabolic rates at other times are not tabulated because few differences from control values were found.
The maximal effect of HAL (1 mg/kg, i.p.) on LCGU declined in relation to age. The number of brain regions in which HAL significantly reduced LCGU fell from 63% of the regions examined in 3-month rats, to 21 to 23% of 12. and 24.month-rats, and to only 10% of 33.month rats. Also, the reduction in the overall mean LCGU in all regions examined was progressively less in older animals. Mean LCGU fell by 21.7% after HAL in 3-month rats, by 13% in 12. and 24-month rats, and by 7.8% in 33.month rats.
The pattern of age-related reductions in the average metabolic response to HAL was apparent also in most of the individual regions examined. Figure 3 depicts the age-dependent decline in the LCGU response to HAL for several representative brain regions.
Regional distribution of LCGU response to HAL. In 3-month-old rats, HAL (1 mg/kg) produced widespread reductions in LCGU (Fig.  4) . Significant decreases were observed in regions containing DA neurons or terminals (e.g., caudate-putamen, globus pallidus, ventral tegmental area, precentral medial cortex) and also in many other regions not known to contain DA terminals or receptors (e.g., most neocortical, cerebellar, and brainstem regions) (Burt et al., 1976; Beckstead et al., 1979) . Significant reductions of LCGU after HAL were seen in only a few brain regions of 33.month rats: frontal cortex, mediodorsal thalamus, subthalamic nucleus, and cerebellar hemispheres. The lateral habenula was the only region in which HAL produced a large elevation in LCGU, and this was observed at all time points at each age.
Discussion
These results show that metabolic sensitivity of the brain of male Fischer-344 rats to the DA antagonist HAL decreases progressively with age after maturity. In 3-month rats, HAL (1 mg/kg) produced widespread reductions of LCGU (63% of the regions; overall mean decline, 21.7%). In 33.month-old rats, only 10% of the regions were significantly affected by HAL, and the overall mean decline was 7.8%. The 12. and 24-month-old animals showed an intermediate response to HAL, indicating that sensitivity to HAL falls progressively throughout maturity.
The maximal catalepsy score also was less in 33.month-old than in 3-month-old rats. The metabolic and behavioral responses also occurred later after HAL administration in the 33-month than in the 3-month-old rats. These findings support the close relation between changes in cerebral metabolism and behavior that we observed also after the DA agonist bromocriptine (Pizzolato et al., 1985a) and after acute and chronic HAL (Pizzolato et al., 1984 (Pizzolato et al., , 1985b ) in 3-monthold rats. The findings are consistent with the reported reduced LCGU response of the aged rat brain to the DA agonist apomorphine (Smith, 1981) .
Pharmacokinetic differences do not account for reduced cerebral metabolic and behavioral responses to HAL in the aged rat. Brain concentrations of HAL in 3-to 4-month and 32. to 34.month-old Fischer-344 rats are similar at 30 min after an acute intraperitoneal injection of the same dose of the drug, but at 60 min and later, they are higher in aged animals because of reduced plasma clearance of HAL (Kapetanovic et al., 1982) . Reduced sensitivity to HAL, therefore, occurs despite higher brain levels of the drug.
The diminishrng effect of HAL on LCGU and on behavior in old rats may be associated with age-dependent, progressive deficits in DA neurotransmission. The activity of tyrosine hydroxylase, the ratelrmitlng enzyme for DA synthesis, is decreased in the aged rat brain (Reis et al., 1977) . Concentrations of DA and of its metabolites in DA regions show progressive, statistically age-correlated declines in rats (Ponzio et al., 1982; Algeri et al., 1983) . DA sensitivity of striatal adenylate cyclase is reduced at 12 and 24.months, compared to 4 months, and is abolished in 30.month-old animals (Puri and Volicer, 1977) . A decreased density of DA receptors has been reported in several brain areas of aged rats (Memo et al., 1980; Misra et al., 1980) mice (Severson and Finch, 1980) rabbits (Thal et al., 1980) and humans (Severson et al., 1982) although the affinity of DA receptors for dopaminergic ligands is not altered (Misra et al., 1980) . Decreases in DA receptor number, which occur in rodents before midlife (Severson and Finch, 1980) progress to 30 to 50% of 3-to 5-month values in rats 24 months and older (Joseph et al., 1981; De Blasi et al., 1982) . This may be due to reduced rates of synthesis of DA receptors in old animals (Henry and Roth, 1984) . As the primary sites of action of HAL are central DA receptors (Creese et al., 1976) age-related changes in DA receptor number and in post-receptor mechanisms, such as adenylate cyclase activity, may contribute to the reduced responsivity of the aged brain to HAL.
Losses of functional interconnections in the aged brain also may contribute to the less widespread effect of HAL in the aged rat. In 3-month-old rats, HAL reduced LCGU in DA regions as well as non-DA regions (Fig. 4) (Burt et al., 1976; Beckstead et al., 1979; Simon et al., 1979) . Significant decreases were found in all neocortical and cerebellar areas, of which only the frontal cortex possesses DA receptors (Thierry et al., 1973; Klemm et al., 1979) . As we noted previously (Pizzolato et al., 1984) , metabolic changes in non-DA regions after HAL may represent an indirect effect, mediated by non-DA pathways that are influenced by DA inputs. Age-related deficits in other neurotransmitter systems, such as the adrenergic (Enna and Strong, 1981; Misra et al., 1980) , GABAergic (Govoni et al., 1980) , and cholinergic (Morin and Westerlain, 1980; Strong et al., 1980) pathways, also could influence the reduction in the number of regions affected by HAL. A generalized age-related reduction in the anatomical complexity of neural circuits (Feldman, 1976; Rogers et al., 1984 ) may contribute to the decreased effect of HAL (and possibly of other drugs) in aged rats. In this study, we found a striking reduction in the metabolic response of the aged rat brain to HAL. The deficit begins within the first third of the mature life span and becomes progressively more severe as the rat ages. The reduced response to HAL correlates with age-dependent losses of functional and biochemical components of the DA system that, in rodents, begin before midlife and progress with age. These deficits probably are related to reduced locomotor activity, rigidity, and impaired motor coordination and balance in senescent rats, and can be reversed by DA agonists or by induced production of new DA receptors (Marshall and Berrios, 1979; Joseph et al., 1983) . In humans, biochemical and receptor markers for the DA system also decline progressively with age (Severson et al., 1982) , and movement disorders occur in the elderly (akinesia and rigidity) that resemble those of Parkinson's disease, a syndrome of DA deficiency (Critchley, 1956; McGeer et al., 1977 ).
Parkinson's disease, it has been suggested that an 80% reduction in the number of DA nigrostriatal projections is required for the clinical symptoms to appear (Hornykiewicz, 1983) . In healthy subjects, motor deficits become apparent only late in life, perhaps when adaptive mechanisms can compensate no longer for losses in the DA system.
Although functional metabolic deficits do not parallel the early degenerative changes of the DA system in resting animals, a reduced functional capacity at 12 and 24 months was demonstrated in this study by a pharmacologic challenge. Drug-induced alterations of the CNS may be useful in detecting early functional deficits in other brain systems during aging.
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